Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.54 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
| ▸ | TK2 | O00142 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627002 | 1.00 | POLB (0.56) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL3626999 | 1.00 | POLB (0.56) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL21011276 | 1.00 | POLB (0.56) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL22942033 | 1.00 | POLB (0.56) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL29983671 | 0.99 | POLB (0.56) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL14429266 | 0.92 | POLB (0.54) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL14429261 | 0.92 | POLB (0.54) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL21545802 | 0.91 | POLB (0.59) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL25971448 | 0.91 | POLB (0.49) | POLBDNMT1ADRB1ABL1RIN1 | |
| SCHEMBL3063781 | 0.90 | DNMT1 (0.56) | POLBDNMT1ADRB1ABL1RIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | AGILENT TECHNOLOGIES, INC. (US) | 2020-03-24 | — | — | US | disclosed |
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | AGILENT TECHNOLOGIES, INC. | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186826-A1 | PROTECTED MONOMER AND METHOD OF FINAL DEPROTECTION FOR RNA SYNTHESIS | NSUN2, RNGTT, RNMT | POLB 37/4885DNMT1 163/4885ADRB1 4843/4885 |
| US-10597421-B2 | Protected monomer and method of final deprotection for RNA synthesis | NSUN2, RNGTT, RNMT | POLB 37/4885DNMT1 163/4885ADRB1 4843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.